The Patent Finder

Terms ending in 2038

Bayer Pharma Aktiengesellschaft

Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 11,142,522Compounds, Compositions and Methods for Cancer Treatment
In force
 · High confidence
Bayer Aktiengesellschaft and Bayer Pharma AktiengesellschaftIn forceHigh confidence
US 11,795,1642-Heteroaryl-3-OXO-2,3-Dihydropyridazine-4-Carboxamides for the Treatment of Cancer
In force
 · Medium confidence
Deutsches KrebsforschungszentrumIn forceMedium confidence
US 12,522,5942-Heteroaryl-3-OXO-2,3-Dihydropyridazine-4-Carboxamides for the Treatment of Cancer
In force
 · Medium confidence
Deutsches KrebsforschungszentrumIn forceMedium confidence
US 11,691,986Ptefb Inhibiting Macrocyclic Compounds
In force
 · Medium confidence
Bayer Aktiengesellschaft and Bayer Pharma AktiengesellschaftIn forceMedium confidence
US 11,976,334Inhibitor of Atr Kinase for Use in a Method of Treating a Hyper-Proliferative Disease
In force
 · Medium confidence
Bayer Aktiengesellschaft and Bayer Pharma AktiengesellschaftIn forceMedium confidence
US 11,684,621Combination Containing SGC Stimulators and Mineralocorticoid Receptor Antagonists
In force
 · Medium confidence
Bayer Pharma AktiengesellschaftIn forceMedium confidence
US 11,433,140Specific Antibody Drug Conjugates (ADCS) Having KSP Inhibitors
In force
 · High confidence
Bayer Pharma AktiengesellschaftIn forceHigh confidence
US 11,098,063Diazabicyclic Substituted Imidazopyrimidines and Their Use for the Treatment of Breathing Disorders
In force
 · High confidence
Bayer Aktiengesellschaft and Bayer Pharma AktiengesellschaftIn forceHigh confidence
US 11,208,422Substituted Bridged Diazepane Derivatives and Use Thereof as TASK-1 and TASK-3 Inhibitors
In force
 · High confidence
Bayer Pharma AktiengesellschaftIn forceHigh confidence
US 12,053,476Compounds, Compositions and Methods for Cancer Patient Stratification and Cancer Treatment
In force
 · Medium confidence
Bayer Pharma AktiengesellschaftIn forceMedium confidence
20 more term ends in 2038 · Pro
10 of 30 patents shown. Soonest term end first, then patent number.
Pro members see all 30.
Upgrade to Pro
22 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited